Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

INCYTE CORPORATION

(INCY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about INCYTE CORPORATION
06/12INCYTE  : Announces Updated Data for Ruxolitinib Cream Accepted for Presentation..
BU
06/11INCYTE  : Review Period for Incyte's Ruxolitinib New Drug Application Extended b..
MT
06/11INCYTE  : Announces U.S. FDA Has Extended the New Drug Application Review Period..
BU
06/08INCYTE  : Says FDA Extends Supplemental New Drug Application Review Period for R..
MT
06/08INCYTE  : Announces U.S. FDA Has Extended the sNDA Review Period for Ruxolitinib..
BU
06/07INCYTE  : MorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND S..
AQ
06/04Germany's MorphoSys, Incyte Say Three-Year Data Backing Tafasitamab Combo in ..
MT
06/04INCYTE  : and MorphoSys Announce Three-Year Results from Phase 2 L-MIND Study of..
BU
06/01INCYTE  : OLUMIANT® Improved Pain, Physical Function and Morning Joint Stiffness..
PR
06/01INCYTE CORPORATION  : Report
CO
05/27INCYTE  : AMENDED AND RESTATED 2010 STOCK INCENTIVE PLAN (Form 8-K)
PU
05/26INCYTE CORPORATION  : Report
CO
05/26INCYTE CORPORATION  : SEC Filing 8K
CO
05/20INCYTE  : to Present at Upcoming Investor Conferences
BU
05/20INCYTE  : Positive Primary Analysis from the Phase 2 OPTIC Study of Ponatinib (I..
BU
More most relevant news
All news about INCYTE CORPORATION
06/12INCYTE  : Announces Updated Data for Ruxolitinib Cream Accepted for Presentation..
BU
06/11Vertex, Incyte fall; Precigen, Magnachip rise
AQ
06/11Stocks Retreat Midday Amid Inflation Worries
MT
06/11MIDDAY REPORT : Wall Street Retreats Midday Amid Inflation Worries
MT
06/11SECTOR UPDATE : Health Care Stocks Slipping Ahead of Friday's Market Open
MT
06/11INCYTE  : Review Period for Incyte's Ruxolitinib New Drug Application Extended b..
MT
06/11INCYTE  : Announces U.S. FDA Has Extended the New Drug Application Review Period..
BU
06/08INCYTE  : Says FDA Extends Supplemental New Drug Application Review Period for R..
MT
06/08INCYTE  : Announces U.S. FDA Has Extended the sNDA Review Period for Ruxolitinib..
BU
06/07INCYTE  : MorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND S..
AQ
More news
News in other languages on INCYTE CORPORATION
06/10MORPHOSYS IM FOKUS : Übernahme von Constellation - ein Meisterstück?
06/07Aktien Frankfurt Eröffnung: Etwas unter jüngsten Rekorden
06/07MORNING BRIEFING - Deutschland/Europa -2-
06/06INCYTE  : und MorphoSys melden Dreijahresergebnisse aus der Phase-2-Studie L-MIN..
06/05INCYTE  : et MorphoSys annoncent les résultats à trois ans de l'étude L-MIND de ..
06/04Morphosys/Incyte melden positive Langzeitergebnisse zu Tafasitamab
06/04DGAP-NEWS : MorphoSys und Incyte geben die -3-
06/04DGAP-NEWS : MorphoSys und Incyte geben die -2-
06/04DGAP-NEWS : MorphoSys und Incyte geben die dreijährigen Ergebnisse der Phase 2 L..
05/20INCYTE  : Positive Primäranalyse der Phase-2-OPTIC-Studie zu Ponatinib (Iclusig®..
More news
Analyst Recommendations on INCYTE CORPORATION
04/19INCYTE  : Credit Suisse Adjusts Incyte's Price Target to $95 from $97, Keeps Neu..
MT
04/05INCYTE  : Morgan Stanley Adjusts Price Target on Incyte to $86 From $93, Maintai..
MT
02/10INCYTE  : Morgan Stanley Adjusts Incyte's Price Target to $93 From $97, Keeps Eq..
MT
02/10INCYTE  : SVB Leerink Downgrades Incyte to Underperform From Market Perform; Pri..
MT
02/10INCYTE  : RBC Capital Adjusts Incyte's Price Target to $93 From $89, Maintains S..
MT
More recommendations
Press releases
06/12INCYTE  : Announces Updated Data for Ruxolitinib Cream Accepted for Presentation..
BU
06/11Vertex, Incyte fall; Precigen, Magnachip rise
AQ
06/11INCYTE  : Announces U.S. FDA Has Extended the New Drug Application Review Period..
BU
06/08INCYTE  : Announces U.S. FDA Has Extended the sNDA Review Period for Ruxolitinib..
BU
06/07INCYTE  : MorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND S..
AQ
More press releases
Official Publications
06/01Report 
05/26SEC Filing 8K 
05/26Report 
05/14Report 
05/04Press Release 
05/041st quarter results